3CWJ | pdb_00003cwj

Crystal structure of hcv ns5b polymerase with a novel pyridazinone inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 
    0.300 (Depositor), 0.298 (DCC) 
  • R-Value Work: 
    0.237 (Depositor), 0.238 (DCC) 
  • R-Value Observed: 
    0.240 (Depositor) 

Starting Model: other
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 3CWJ

Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history

Literature

4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase

Ellis, D.A.Blazel, J.K.Webber, S.E.Tran, C.V.Dragovich, P.S.Sun, Z.Ruebsam, F.McGuire, H.M.Xiang, A.X.Zhao, J.Li, L.S.Zhou, Y.Han, Q.Kissinger, C.R.Showalter, R.E.Lardy, M.Shah, A.M.Tsan, M.Patel, R.LeBrun, L.A.Kamran, R.Bartkowski, D.M.Nolan, T.G.Norris, D.A.Sergeeva, M.V.Kirkovsky, L.

(2008) Bioorg Med Chem Lett 18: 4628-4632

  • DOI: https://doi.org/10.1016/j.bmcl.2008.07.014
  • Primary Citation Related Structures: 
    3CWJ

  • PubMed Abstract: 

    4-(1,1-Dioxo-1,4-dihydro-1lambda(6)-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-one analogs were discovered as a novel class of inhibitors of HCV NS5B polymerase. Structure-based design led to the identification of compound 3a that displayed potent inhibitory activities in biochemical and replicon assays (1b IC(50)<10 nM; 1b EC(50)=1.1 nM) as well as good stability toward human liver microsomes (HLM t(1/2)>60 min).


  • Organizational Affiliation
    • Anadys Pharmaceuticals, Inc., 3115 Merryfield Row, San Diego, CA 92121, USA.

Macromolecule Content 

  • Total Structure Weight: 129.76 kDa 
  • Atom Count: 8,947 
  • Modeled Residue Count: 1,114 
  • Deposited Residue Count: 1,156 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
RNA-DIRECTED RNA POLYMERASE
A, B
578N/AMutation(s): 0 
EC: 2.7.7.48
UniProt
Find proteins for P26663 (Hepatitis C virus genotype 1b (isolate BK))
Explore P26663 
Go to UniProtKB:  P26663
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP26663
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
321

Query on 321



Download:Ideal Coordinates CCD File
C [auth A],
D [auth B]
N-{3-[5-hydroxy-2-(3-methylbutyl)-3-oxo-6-thiophen-2-yl-2,3-dihydropyridazin-4-yl]-1,1-dioxido-2H-1,4-benzothiazin-7-yl}methanesulfonamide
C22 H24 N4 O6 S3
KLPXSYJOJCQFSY-UHFFFAOYSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
321 BindingDB:  3CWJ IC50: 10 (nM) from 1 assay(s)
EC50: min: 1.1, max: 11 (nM) from 2 assay(s)

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free:  0.300 (Depositor), 0.298 (DCC) 
  • R-Value Work:  0.237 (Depositor), 0.238 (DCC) 
  • R-Value Observed: 0.240 (Depositor) 
Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 86.107α = 90
b = 106.393β = 90
c = 126.731γ = 90
Software Package:
Software NamePurpose
CrystalCleardata collection
EPMRphasing
REFMACrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2009-04-21
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2024-04-03
    Changes: Data collection, Database references, Derived calculations, Refinement description
  • Version 1.3: 2024-10-30
    Changes: Structure summary